This site is intended for US healthcare professionals only

What is Optune Lua?

Patients remain at the heart of the work we do every day, including our innovations in the Optune Lua device for patients living with MPM

Original Optune^® system

Second-generation Optune Lua system

Designed for more convenience, carrying comfort and usability—the second-generation Optune Lua system is²:

More compact

Smaller-profile carrying case with easy-grip texture

More convenient

5 different ways to carry the device

Equipped with smart technology

Battery indicator alerts patients to change battery and light sensor auto-dims for night use

Loco-regional delivery of Tumor Treating Fields (TTFields) via transducer arrays provides antimitotic activity directly at the site of the malignancy¹

Actor portrayal

TTFields are added to pemetrexed + cisplatin or carboplatin systemic therapies
The size and placement of transducer arrays are customized based on gender, body type, and tumor location
- Novocure^® will provide a customized map for array placement based on patient-specific measurements and tumor location (determined via CT scans).
It is recommended that Optune Lua is turned on at least 75% of the time (18 hours per day)
- Patients have the flexibility to decide which times of the day are best for them, including at night when sleeping

Next: Mechanism of Action

MPM, malignant pleural mesothelioma.

References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021. 2. Optune Lua. Patient Information and Operation Manual for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021.

Important Safety Information

Contraindications

Do not use Optune Lua in patients with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc. Use of Optune Lua together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure^®.

The most common (≥10%) adverse events involving Optune Lua in combination with chemotherapy were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Do not prescribe Optune Lua for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

Please click here to see Optune Lua Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.